ViV-TAVI showed higher mean aortic valve gradient by 0.72 mmHg, 2.89-fold increased paravalvular leak risk, and up to 1.68-fold higher patient-prosthesis mismatch risk vs reSAVR.
Does ViV-TAVI improve post-procedural valve hemodynamics compared to reSAVR in patients with a degenerated bioprosthetic aortic valve?
ViV-TAVI results in suboptimal valve hemodynamics, including higher gradients, more paravalvular leak, and increased severe patient-prosthesis mismatch, compared to redo surgical aortic valve replacement.
Absolute Event Rate: 0% vs 0%
Abstract Background Valve in Valve Transcatheter Aortic Valve Implantation (ViV-TAVI) has recently emerged as a safe and efficient alternative to repeat surgery (reSAVR) for patients with a degenerated, surgically implanted, bioprosthetic aortic valve. Purpose The aim of this meta-analysis is to compare the two interventions regarding echocardiographic, post-intervention parameters, in order to assess valve hemodynamics. Methods A systematic search was performed in 3 different databases (PubMed, Web of Science, Scopus) from their inception until June 2023. All trials, which met the prespecified inclusion criteria, were included to the meta-analysis, according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines and a random effect meta-analysis was then performed. Results A total of 26 studies were included. The total population of this analysis included 17,581 patients, out of which 9,163 underwent ViV-TAVI and 8,418 underwent reSAVR. Post procedural echocardiography showed that patients in the ViV-TAVI had greater mean aortic valve (AV) gradient, compared to the reSAVR arm mean difference: 0.72, 95% Confidence Interval (CI): 0.30-1.14. Furthermore, post-intervention paravalvular leak was also significantly increased after ViV-TAVI Relative Risk (RR): 2.89; 95%CI: 1.79 to 4.66. Finally, ViV-TAVI was associated with greater risk for developing patient-prosthesis mismatch (PPM) (RR: 1.68; 95%CI: 0.74-3.81), as well as for severe PPM (RR: 1.62; 95%CI: 1.04-2.52). Conclusion This metanalysis shows that ViV-TAVI results in suboptimal valve hemodynamics, compared to reSAVR. As pre-procedural planning and valve technology for ViV procedures continues to emerge, future ViV-TAVI interventions should aim in the best achievable valve implantation utilizing such tools, in order to ensure proper valve function, dynamics and potentially and enhanced valve longevity.
Pyrpyris et al. (Sat,) reported a other. ViV-TAVI showed higher mean aortic valve gradient by 0.72 mmHg, 2.89-fold increased paravalvular leak risk, and up to 1.68-fold higher patient-prosthesis mismatch risk vs reSAVR.